Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-11-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于作废部分已授予尚未归属的2020年限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shanghai Medicilon Biopharmaceutical Co., Ltd. regarding the cancellation of part of the 2020 restricted stock that was granted but not yet vested. It details board and supervisory meetings, legal opinions, and compliance with relevant laws and regulations. The content focuses on corporate governance actions related to stock incentive plans, specifically the cancellation of unvested restricted shares. There is no financial statement or detailed financial performance data presented. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is a formal announcement about a management decision affecting share incentives, which aligns with announcements about changes in management-related equity plans. This fits best under the category of Board/Management Information (MANG), as it involves board resolutions and management decisions about stock incentives and their cancellation.
2022-11-14 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司首次公开发行限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It references regulatory approvals, shareholding details, lock-up periods, shareholder commitments, and compliance with relevant securities laws and listing rules. The document does not present financial statements or earnings data but focuses on the regulatory and compliance aspects of share circulation post-IPO. This type of document is typically classified as a Regulatory Filing (RNS) because it is a compliance and regulatory disclosure related to share circulation and lock-up release, not a financial report or announcement of voting results or capital changes. The document length is moderate and contains substantive content, but it is not an annual or interim report, nor an earnings release or capital update. Therefore, the best fit is Regulatory Filings (RNS).
2022-11-01 Chinese
美迪西：首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming tradable, the lock-up period expiration, shareholder commitments, and compliance with regulatory requirements. It references regulatory approvals and stock exchange rules but does not contain financial statements or detailed financial performance data. The document is primarily about the unlocking and circulation of restricted shares, which is a capital structure event rather than a financial report or earnings release. It is not a full annual or interim report, nor is it a simple notice of dividend or voting results. Given the content and nature, this fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as restricted shares becoming tradable.
2022-11-01 Chinese
美迪西：独立董事关于第三届董事会第十次会议相关事项的独立意见
Regulatory Filings
2022-10-30 Chinese
美迪西：关于公司董事辞职的公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Shanghai Medicilon Inc. regarding the resignation of a company director, Mr. Chen Jianhuang. It includes statements about the resignation's effect on the board and the company's operations, and expresses gratitude for the director's contributions. There is no financial data, no mention of reports or filings, and the content focuses solely on a change in the company's board of directors. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing, but a direct announcement of a board change.
2022-10-30 Chinese
美迪西：第三届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shanghai Medicilon Inc. regarding the approval of the company's 2022 third quarter report and the use of temporarily idle raised funds for cash management. It references the 2022 third quarter report but does not contain the report itself or detailed financial data. The document is short (1280 characters) and mainly announces the supervisory board's approval and meeting details. It also directs readers to the full report published on the Shanghai Stock Exchange website. Therefore, this document is an announcement related to the supervisory board meeting and approvals, not the actual quarterly report or financial statements. It fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and approvals without substantive financial data included.
2022-10-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.